Audentes Prices $75M IPO As Gene Therapy Eyes First U.S. Approval
Xconomy
JULY 20, 2016
Gene therapy’s multi-decade roller-coaster ride has been well documented, in Xconomy and elsewhere. million in equity financing since its 2012 inception, and had $80.3 The promise of shuttling a long-term, if not permanent genetic fix into a patient with a one-time treatment has tantalized scientists for years.
Let's personalize your content